{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:37:31Z","timestamp":1789137451907,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T00:00:00Z","timestamp":1552089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004442","name":"Narodowym Centrum Nauki","doi-asserted-by":"publisher","award":["2017\/25\/N\/NZ2\/00812"],"award-info":[{"award-number":["2017\/25\/N\/NZ2\/00812"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s11011-019-00405-4","type":"journal-article","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T00:53:32Z","timestamp":1552092812000},"page":"715-720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington\u2019s disease patients"],"prefix":"10.1007","volume":"34","author":[{"given":"Karolina","family":"Pierzynowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gaffke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Cyske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4042-7466","authenticated-orcid":false,"given":"Grzegorz","family":"W\u0119grzyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,9]]},"reference":[{"key":"405_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrd3050","volume":"9","author":"A Aguzzi","year":"2010","unstructured":"Aguzzi A, O\u2019Connor T (2010) Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 9:237\u2013248","journal-title":"Nat Rev Drug Discov"},{"key":"405_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bpa.12545","volume":"28","author":"F Guo","year":"2018","unstructured":"Guo F, Liu X, Cai H, Le W (2018) Autophagy in neurodegenerative diseases: pathogenesis and therapy. Brain Pathol 28:3\u201313","journal-title":"Brain Pathol"},{"key":"405_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group (1996) Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov Disord 11:136\u2013142","journal-title":"Mov Disord"},{"key":"405_CR4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s11011-017-0026-0","volume":"32","author":"P J\u0119drak","year":"2017","unstructured":"J\u0119drak P, Krygier M, To\u0144ska K et al (2017a) Mitochondrial DNA levels in Huntington disease leukocytes and dermal fibroblasts. Metab Brain Dis 32:1237\u20131247","journal-title":"Metab Brain Dis"},{"key":"405_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.18388\/abp.2017_2303","volume":"64","author":"P J\u0119drak","year":"2017","unstructured":"J\u0119drak P, Sowa N, Bara\u0144ska S, W\u0119grzyn G (2017b) Characterization of conditions and determination of practical tips for mtDNA level estimation in various human cells. Acta Biochim Pol 64:699\u2013704","journal-title":"Acta Biochim Pol"},{"key":"405_CR6","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s11011-018-0308-1","volume":"33","author":"P J\u0119drak","year":"2018","unstructured":"J\u0119drak P, Mozolewski P, W\u0119grzyn G, Wi\u0119ckowski MR (2018) Mitochondrial alterations accompanied by oxidative stress conditions in skin fibroblasts of Huntington's disease patients. Metab Brain Dis 33:2005\u20132017","journal-title":"Metab Brain Dis"},{"key":"405_CR7","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.1074\/jbc.M103946200","volume":"277","author":"KB Kegel","year":"2002","unstructured":"Kegel KB, Meloni AR, Yi Y et al (2002) Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem 277:7466\u20137476","journal-title":"J Biol Chem"},{"key":"405_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ymgme.2013.06.012","volume":"109","author":"KH Kim","year":"2013","unstructured":"Kim KH, Dodsworth C, Paras A, Burton BK (2013) High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system. Mol Genet Metab 109:382\u2013385","journal-title":"Mol Genet Metab"},{"key":"405_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ymgme.2009.06.013","volume":"98","author":"M Malinowska","year":"2009","unstructured":"Malinowska M, Wilkinson FL, Bennett W, Langford-Smith KJ, O'Leary HA, Jakobkiewicz-Banecka J, Wynn R, Wraith JE, Wegrzyn G, Bigger BW (2009) Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab 98:235\u2013242","journal-title":"Mol Genet Metab"},{"key":"405_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014192","volume":"5","author":"M Malinowska","year":"2010","unstructured":"Malinowska M, Wilkinson FL, Langford-Smith KJ, Langford-Smith A, Brown JR, Crawford BE, Vanier MT, Grynkiewicz G, Wynn RF, Wraith JE, Wegrzyn G, Bigger BW (2010) Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 5:e14192","journal-title":"PLoS One"},{"key":"405_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jns.2013.11.014","volume":"337","author":"E Marchina","year":"2014","unstructured":"Marchina E, Misasi S, Bozzato A et al (2014) Gene expression profile in fibroblasts of Huntington\u2019s disease patients and controls. J Neurol Sci 337:42\u201346","journal-title":"J Neurol Sci"},{"key":"405_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000369111","volume":"34","author":"MK Morreale","year":"2015","unstructured":"Morreale MK (2015) Huntington's disease: looking beyond the movement disorder. Adv Psychosom Med 34:135\u2013142","journal-title":"Adv Psychosom Med"},{"key":"405_CR13","doi-asserted-by":"publisher","first-page":"17054","DOI":"10.1074\/jbc.M114.555300","volume":"289","author":"M Moskot","year":"2014","unstructured":"Moskot M, Montefusco S, Jak\u00f3bkiewicz-Banecka J, Mozolewski P, W\u0119grzyn A, Di Bernardo D, W\u0119grzyn G, Medina DL, Ballabio A, Gabig-Cimi\u0144ska M (2014) The phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activation. J Biol Chem 289:17054\u201317069","journal-title":"J Biol Chem"},{"key":"405_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.mito.2014.05.001","volume":"17","author":"MH Petersen","year":"2014","unstructured":"Petersen MH, Budtz-J\u00f8rgensen E, S\u00f8rensen SA et al (2014) Reduction in mitochondrial DNA copy number in peripheral leukocytes after onset of Huntington\u2019s disease. Mitochondrion 17:14\u201321","journal-title":"Mitochondrion"},{"key":"405_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s11011-018-0214-6","volume":"33","author":"K Pierzynowska","year":"2018","unstructured":"Pierzynowska K, Gaffke L, Cyske Z, Puchalski M, Rintz E, Bartkowski M, Osiad\u0142y M, Pierzynowski M, Mantej J, Piotrowska E, W\u0119grzyn G (2018a) Autophagy stimulation as a promising approach in treatment of neurodegenerative diseases. Metab Brain Dis 33:989\u20131008","journal-title":"Metab Brain Dis"},{"key":"405_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s12017-018-8482-1","volume":"20","author":"K Pierzynowska","year":"2018","unstructured":"Pierzynowska K, Gaffke L, Ha\u0107 A, Mantej J, Niedzia\u0142ek N, Brokowska J, W\u0119grzyn G (2018b) Correction of Huntington's disease phenotype by genistein-induced autophagy in the cellular model. NeuroMolecular Med 20:112\u2013123","journal-title":"NeuroMolecular Med"},{"key":"405_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.neuropharm.2019.01.030","volume":"148","author":"K Pierzynowska","year":"2019","unstructured":"Pierzynowska K, Podlacha M, Gaffke L, Majkutewicz I, Mantej J, Wegrzyn A, Osiad\u0142y M, Myslinska D, Wegrzyn G (2019) Autophagy-dependent mechanism of genistein-mediated elimination of behavioral and biochemical defects in the rat model of sporadic Alzheimer's disease. Neuropharmacology 148:332\u2013346","journal-title":"Neuropharmacology"},{"key":"405_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.expneurol.2009.05.012","volume":"219","author":"J Sassone","year":"2009","unstructured":"Sassone J, Colciago C, Cislaghi G et al (2009) Huntington\u2019s disease: the current state of research with peripheral tissues. Exp Neurol 219:385\u2013397","journal-title":"Exp Neurol"},{"key":"405_CR19","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/mds.26331","volume":"30","author":"KM Shannon","year":"2015","unstructured":"Shannon KM, Fraint A (2015) Therapeutic advances in Huntington's disease. Mov Disord 30:1539\u20131546","journal-title":"Mov Disord"},{"key":"405_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/0896-6273(95)90345-3","volume":"14","author":"AH Sharp","year":"1995","unstructured":"Sharp AH, Loev SJ, Schilling G et al (1995) Widespread expression of Huntington\u2019s disease gene (IT15) protein product. Neuron 14:1065\u20131074","journal-title":"Neuron"},{"key":"405_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212337","volume":"14","author":"A Tousley","year":"2019","unstructured":"Tousley A, Iuliano M, Weisman E, Sapp E, Richardson H, Vodicka P, Alexander J, Aronin N, DiFiglia M, Kegel-Gleason KB (2019) Huntingtin associates with the actin cytoskeleton and \u03b1-actinin isoforms to influence stimulus dependent morphology changes. PLoS One 14:e0212337","journal-title":"PLoS One"},{"key":"405_CR22","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.4103\/1673-5374.235250","volume":"13","author":"HC Wu","year":"2018","unstructured":"Wu HC, Hu QL, Zhang SJ, Wang YM, Jin ZK, Lv LF, Zhang S, Liu ZL, Wu HL, Cheng OM (2018) Neuroprotective effects of genistein on SH-SY5Y cells overexpressing A53T mutant \u03b1-synuclein. Neural Regen Res 13:1375\u20131383","journal-title":"Neural Regen Res"},{"key":"405_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/aps.2013.5","volume":"34","author":"YP Yang","year":"2013","unstructured":"Yang YP, Hu LF, Zheng HF, Mao CJ, Hu WD, Xiong KP, Wang F, Liu CF (2013) Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol Sin 34:625\u2013635","journal-title":"Acta Pharmacol Sin"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-019-00405-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-019-00405-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-019-00405-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,8]],"date-time":"2020-03-08T00:13:54Z","timestamp":1583626434000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-019-00405-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["405"],"URL":"https:\/\/doi.org\/10.1007\/s11011-019-00405-4","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,9]]},"assertion":[{"value":"17 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The use of genistein in treatment of Huntington\u2019s disease is a subject of patent application (no. P.417983, submitted to Polish Patent Office). No other conflicts of interest are declared by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}